EUVIMEDEUVIMED entdecken
Crossref

Four-year evaluation of neonatal cystic fibrosis screening in Southern Belgium

M Thimmesch, S Berardis, L Hanssens, C Quentin, F Boemer, G Luis, J P Dewulf, S Marie, L Marcelis, N Lefèvre, C Libioulle, V Dideberg und 3 weitere

European Journal of Pediatrics · 2024

DOI: 10.1007/s00431-024-05845-4 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Pediatrics, 2024. Verfasst von M Thimmesch und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatric Pulmonology and Cystic Fibrosis, Centre Hospitalier Chrétien MontLégia, Liège, Belgium. matthieu.thimmesch@gmail.com. Hauptthemen laut MEDLINE: Cystic Fibrosis, Neonatal Screening, Cystic Fibrosis Transmembrane Conductance Regulator. Die Arbeit nennt 12 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Newborn screening for cystic fibrosis (CF-NBS) using an IRT-DNA algorithm with a 12 CFTR-variant panel and an IRT/IRT failsafe was officially implemented in the French-speaking Community of Belgium in January 2020. This screening protocol was evaluated after 4 years according to the criteria defined by the European Cystic Fibrosis Society's working group on neonatal screening. Immunoreactive trypsinogen concentration (IRT) was measured on dried blood spots collected between the second and the fourth day of life. CFTR variants genotyping was initiated when IRT ≥ 99th percentile (P99). If at least 1 variant was identified, the child was referred to a CF center for a sweat test (ST). If IRT ≥ 99.9th percentile with no variant identified, a failsafe was provided with IRT repeated on day 21 and subsequent ST in case of persistent IRT > P99. Extensive Gene Analysis was initiated if sweat chloride level was ≥ 30 mmol/L. Over a period of 4 years, 212.979 newborns were screened. Forty-two were diagnosed with CF: 34 by CF-NBS, 3 following a meconium ileus, 3 by family history and 2 missed cases. Additionally, 112 healthy carriers and 14 CFSPID were identified. The median age at the first consultation was 23 days. The sensitivity of our CF-NBS is 95% (target ≥ 95%), the positive predictive value 18% (target ≥ 30%) and CF/CFSPID ratio 2.8. CONCLUSION: Although follow-up is limited, this first evaluation demonstrates encouraging sensitivity and early management before one month of age. WHAT IS KNOWN: • Newborn screening for cystic fibrosis improves the prognosis of patients. WHAT IS NEW: • This article presents an initial assessment of our screening after 4 years.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cystic FibrosisNeonatal ScreeningCystic Fibrosis Transmembrane Conductance RegulatorHumansInfant, NewbornBelgiumFemaleMaleGenetic TestingTrypsinogenSweatGenotypeAlgorithms

Stichwörter der Autor:innen

Cystic fibrosisImmunoreactive trypsinogenNewborn screening

Substanzen

Cystic Fibrosis Transmembrane Conductance RegulatorCFTR protein, humanTrypsinogen

Autor:innen und Institutionen

  • Department of Pediatric Pulmonology and Cystic Fibrosis, Centre Hospitalier Chrétien MontLégia, Liège, Belgium. matthieu.thimmesch@gmail.com.
  • Department of Pediatric Pulmonology and Cystic Fibrosis, Cliniques universitaires Saint-Luc, Brussels, Belgium.
  • Department of Pediatric Pulmonology and Cystic Fibrosis, Hôpital Universitaire des enfants Reine Fabiola, Brussels, Belgium.
  • Biochemical Genetics and Newborn Screening Laboratory, Department of Genetics, Centre Hospitalier Universitaire de Liège, Liège, Belgium.
  • Biochemical Genetics and Newborn Screening Laboratory, Department of Clinical Chemistry, Cliniques Universitaires Saint-Luc, Brussels, Belgium.
  • Laboratory of Pediatric Research - Brussels Newborn Screening Center, Université libre de Bruxelles, Brussels, Belgium.

Zitieren

APA

Thimmesch, M., Berardis, S., Hanssens, L., Quentin, C., Boemer, F., Luis, G., Dewulf, J. P., Marie, S., Marcelis, L., Lefèvre, N., Libioulle, C., Dideberg, V., Philippeau, M., Revencu, N., & Boboli, H. (2024). Four-year evaluation of neonatal cystic fibrosis screening in Southern Belgium. European Journal of Pediatrics. https://doi.org/10.1007/s00431-024-05845-4

Vancouver

Thimmesch M, Berardis S, Hanssens L, Quentin C, Boemer F, Luis G, et al. Four-year evaluation of neonatal cystic fibrosis screening in Southern Belgium. European Journal of Pediatrics. 2024. doi:10.1007/s00431-024-05845-4

BibTeX
@article{Thimmesch2024,
  author = {Thimmesch, M and Berardis, S and Hanssens, L and Quentin, C and Boemer, F and Luis, G and Dewulf, J P and Marie, S and Marcelis, L and Lefèvre, N and Libioulle, C and Dideberg, V and Philippeau, M and Revencu, N and Boboli, H},
  title = {Four-year evaluation of neonatal cystic fibrosis screening in Southern Belgium},
  journal = {European Journal of Pediatrics},
  year = {2024},
  doi = {10.1007/s00431-024-05845-4}
}
Kostenlos starten →